MedPath

Applying pGz in Mitochondrial Disease

Phase 1
Recruiting
Conditions
Mitochondrial Myopathies
Mitochondrial Diseases
Interventions
Diagnostic Test: Cardiopulmonary Exercise Testing
Device: pGz Bed
Device: Exercise Pedal
Device: Gentle Jogger
Registration Number
NCT05569122
Lead Sponsor
Children's Hospital of Philadelphia
Brief Summary

This is a multi-aim study, studying the effects of conventional exercise (measured through Cardiopulomary Exercises Testing or an in-bed pedal exercise) and passive exercise through periodic acceleration (pGz). Aim 1 will focus on the differences between primary mitochondrial disease (PMD) patients and healthy volunteers. Aim 2 is an exploratory aim, which will be studying the effects in patients admitted to the Children's Hospital of Philadelphia Pediatric Intensive Care Unit (PICU).

Detailed Description

Aim 1: Primary Mitochondrial Disease Patients and Healthy Controls

Individuals will be screened for eligibility for study entry, and answer questions relating to their ability to perform study procedures and their physical activity levels. Individuals who meet study criteria will have 3 study visits, and each study visit will involve a different intervention.

At each of these study visits, individuals will complete one of the following interventions: Cardiopulmonary Exercise Testing (CPET), pGz administration through a bed or recliner, and pGz through a device called a Gentle Jogger. While participants will complete all three study visits, the order of the study visits will occur in random order.

During the study visits, participants will have blood draws before and after the study intervention, a vascular ultrasound with a Lumason contrast agent before and after the study intervention, and a Creatine Chemical Exchange Saturation Transfer (CrCEST) MRI of the lower leg.

Aim 2: Patients in the Pediatric Intensive Care Unit (PICU)

Individuals will be screened for eligibility for study entry. Individuals who meet study criteria will have 2 study visits during their admission to the PICU. The first study visit will involve a pedal exercise and the second study visit will involve pGz administration through a device called a Gentle Jogger.

During the study visits, participants will have blood draws before and after the study intervention, a vascular ultrasound with a Lumason contrast agent before and after the study intervention, and if able to safely complete, an CrCEST MRI of the lower leg.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Aim 2: PICU PatientsLumason® contrast agentAll participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
Aim 1: Healthy ControlsGentle JoggerThe participant has the interventions/study visits occur in a random order: pGz administration through Gentle Jogger CPET pGz administration through pGz Bed
Aim 1: Primary Mitochondrial Disease PatientsCardiopulmonary Exercise TestingThe participant has the interventions/study visits occur in a random order: CPET pGz administration through pGz Bed pGz administration through Gentle Jogger
Aim 1: Primary Mitochondrial Disease PatientspGz BedThe participant has the interventions/study visits occur in a random order: CPET pGz administration through pGz Bed pGz administration through Gentle Jogger
Aim 1: Primary Mitochondrial Disease PatientsGentle JoggerThe participant has the interventions/study visits occur in a random order: CPET pGz administration through pGz Bed pGz administration through Gentle Jogger
Aim 1: Primary Mitochondrial Disease PatientsLumason® contrast agentThe participant has the interventions/study visits occur in a random order: CPET pGz administration through pGz Bed pGz administration through Gentle Jogger
Aim 1: Healthy ControlsCardiopulmonary Exercise TestingThe participant has the interventions/study visits occur in a random order: pGz administration through Gentle Jogger CPET pGz administration through pGz Bed
Aim 1: Healthy ControlspGz BedThe participant has the interventions/study visits occur in a random order: pGz administration through Gentle Jogger CPET pGz administration through pGz Bed
Aim 1: Healthy ControlsLumason® contrast agentThe participant has the interventions/study visits occur in a random order: pGz administration through Gentle Jogger CPET pGz administration through pGz Bed
Aim 2: PICU PatientsGentle JoggerAll participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
Aim 2: PICU PatientsExercise PedalAll participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
Primary Outcome Measures
NameTimeMethod
Aim 1 and 2: Oxygen Consumption1 hour per study intervention

Measured During the study interventions

Aim 1: Mean Difference in Maximal Oxygen Consumption between primary mitochondrial disease patients and healthy volunteersDuring Cardiopulmonary Exercise Testing, which will last 1 hour

Maximal Oxygen Consumption will be measured only during CPET

Aim 2: Arterial-Venous (A-V) O2 differenceA total of 4 15 minute blood draws

This will be measured through blood draws that occur before and after study interventions

Secondary Outcome Measures
NameTimeMethod
Post-operative Patient Satisfaction Survey15 minutes, taken after each study intervention

Participant tolerance to pGz compared to CPET

Borg Scale15 minutes, taken after each study intervention

Participant tolerance to pGz compared to CPET

Aim 1 and 2: A/B ratio measurement through EKG or Plethsymography1 hour per study intervention

To measure hemodynamic physiologic marker of cardiac output (CO)

Aim 1 and 2: Heart Rate1 hour per study intervention

To measure hemodynamic physiologic marker of cardiac output (CO)

Aim 1 and 2: OXPHOS CapacityAim 1 subjects will complete 2 1 hour MRIs, Aim 2 Subjects will complete 1 1-hour MRI

Measured through a CrCEST Leg MRI, which measures creative levels and recovery in the leg

Aim 1 and 2: Plasma Lactate Levels15 minute blood draws that occur pre and and immediately after each study intervention

Measured through venous blood draws

Aim 1 and 2: Vasodilatation30 minute ultrasound that occurs pre and immediately after each study intervention

Measured through a vascular ultrasound with contrast

NO release15 minutes, before and immediately after each study intervention

Measured through Plethsymography

Plasma Nom Levels15 minute blood draws that occur pre and immediately after each study intervention

Measured through venous blood draws

Trial Locations

Locations (1)

Children's Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath